• Return to Headlines

Relatively High Debt to EBITDA Ratio Detected in Shares of Ionis Pharmaceut in the Biotechnology Industry (IONS, AMAG, LGND, PGNX, RGEN)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the highest debt to EBITDA ratios. This ratio indicates how many years of EBITDA would be necessary in order to pay back all the debt (assuming Debt and EBITDA are constant). Typically, this ratio is considered to be alarming when it is greater than 3.0 but this can vary and should be looked at within the context of the industry.

Ionis Pharmaceut ranks highest with a a debt to EBITDA ratio of 18.9. Amag Pharmaceuti is next with a a debt to EBITDA ratio of 7.8. Ligand Pharm ranks third highest with a a debt to EBITDA ratio of 4.2.

Progenics Pharm follows with a a debt to EBITDA ratio of 4.0, and Repligen Corp rounds out the top five with a a debt to EBITDA ratio of 4.0.

SmarTrend recommended that subscribers consider buying shares of Repligen Corp on February 23rd, 2017 as our technology indicated a new Uptrend was in progress when shares hit $32.17. Since that recommendation, shares of Repligen Corp have risen 35.2%. We continue to monitor Repligen Corp for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest debt to ebitda ratio ionis pharmaceut amag pharmaceuti ligand pharm progenics pharm repligen corp

Ticker(s): IONS AMAG LGND PGNX RGEN